Novel findings in relation to multiple anti-atherosclerotic effects of XueZhiKang in humans
Background: Previous studies have clearly demonstrated that XueZhiKang (XZK), an extract of cholestin, can decrease low-density lipoprotein cholesterol (LDL-C) and cardiovascular events. However, the mechanism of the effects of XZK on atherosclerosis (AS) in humans has been reported less frequently....
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
KeAi Communications Co., Ltd.
2018
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/4208be07430f456da1559d68db4ce26a |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:4208be07430f456da1559d68db4ce26a |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:4208be07430f456da1559d68db4ce26a2021-12-02T13:21:26ZNovel findings in relation to multiple anti-atherosclerotic effects of XueZhiKang in humans2095-882X10.1016/j.cdtm.2017.09.004https://doaj.org/article/4208be07430f456da1559d68db4ce26a2018-06-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2095882X17300610https://doaj.org/toc/2095-882XBackground: Previous studies have clearly demonstrated that XueZhiKang (XZK), an extract of cholestin, can decrease low-density lipoprotein cholesterol (LDL-C) and cardiovascular events. However, the mechanism of the effects of XZK on atherosclerosis (AS) in humans has been reported less frequently. In the present study, we investigated the impact of XZK on lipoprotein subfractions, oxidized LDL (oxLDL), and interleukin-6 (IL-6). Methods: From October 2015 to July 2016, 40 subjects were enrolled in this study. Of them, 20 subjects with dyslipidemia received XZK 1200 mg/day for 8 weeks (XZK group); 20 additional healthy subjects who did not receive therapy acted as controls. The plasma lipoprotein subfractions, oxLDL, and IL-6 were examined at baseline and again at 8 weeks. Results: Data showed that XZK could significantly decrease not only plasma LDL-C levels (87.26 ± 24.45 vs. 123.34 ± 23.99, P < 0.001), total cholesterol (4.14 ± 0.87 vs. 5.08 ± 1.03, P < 0.001), triglycerides (0.95 ± 0.38 vs. 1.55 ± 0.61, P < 0.05), and apolipoprotein B (1.70 ± 0.35 vs. 1.81 ± 0.72, P < 0.05), but also oxLDL (36.36 ± 5.31 vs. 49.20 ± 15.01, P < 0.05) and IL-6 (8.50 ± 7.40 vs. 10.40 ± 9.49, P < 0.05). At the same time, XZK reduced the concentration of small LDL-C (1.78 ± 2.17 vs. 6.33 ± 7.78, P < 0.05) and the percentage of the small LDL subfraction (1.09 ± 1.12 vs. 3.07 ± 3.09, P < 0.05). Conclusions: Treatment with 1200 mg/day XZK for 8 weeks significantly decreased the atherogenic small LDL subfraction and reduced oxidative stress and inflammatory markers, in addition to affecting the lipid profile, suggesting multiple beneficial effects in coronary artery disease. Keywords: XueZhiKang, Hyperlipidemia, Low-density lipoprotein cholesterol subfraction, Oxidized LDL, Interleukin-6Rui-Xia XuYan ZhangYuan-Lin GuoChun-Yan MaYu-Hong YaoSha LiXiao-Lin LiPing QingYing GaoNa-Qiong WuCheng-Gang ZhuGeng LiuQian DongJing SunJian-Jun LiKeAi Communications Co., Ltd.articleMedicine (General)R5-920ENChronic Diseases and Translational Medicine, Vol 4, Iss 2, Pp 117-126 (2018) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine (General) R5-920 |
| spellingShingle |
Medicine (General) R5-920 Rui-Xia Xu Yan Zhang Yuan-Lin Guo Chun-Yan Ma Yu-Hong Yao Sha Li Xiao-Lin Li Ping Qing Ying Gao Na-Qiong Wu Cheng-Gang Zhu Geng Liu Qian Dong Jing Sun Jian-Jun Li Novel findings in relation to multiple anti-atherosclerotic effects of XueZhiKang in humans |
| description |
Background: Previous studies have clearly demonstrated that XueZhiKang (XZK), an extract of cholestin, can decrease low-density lipoprotein cholesterol (LDL-C) and cardiovascular events. However, the mechanism of the effects of XZK on atherosclerosis (AS) in humans has been reported less frequently. In the present study, we investigated the impact of XZK on lipoprotein subfractions, oxidized LDL (oxLDL), and interleukin-6 (IL-6). Methods: From October 2015 to July 2016, 40 subjects were enrolled in this study. Of them, 20 subjects with dyslipidemia received XZK 1200 mg/day for 8 weeks (XZK group); 20 additional healthy subjects who did not receive therapy acted as controls. The plasma lipoprotein subfractions, oxLDL, and IL-6 were examined at baseline and again at 8 weeks. Results: Data showed that XZK could significantly decrease not only plasma LDL-C levels (87.26 ± 24.45 vs. 123.34 ± 23.99, P < 0.001), total cholesterol (4.14 ± 0.87 vs. 5.08 ± 1.03, P < 0.001), triglycerides (0.95 ± 0.38 vs. 1.55 ± 0.61, P < 0.05), and apolipoprotein B (1.70 ± 0.35 vs. 1.81 ± 0.72, P < 0.05), but also oxLDL (36.36 ± 5.31 vs. 49.20 ± 15.01, P < 0.05) and IL-6 (8.50 ± 7.40 vs. 10.40 ± 9.49, P < 0.05). At the same time, XZK reduced the concentration of small LDL-C (1.78 ± 2.17 vs. 6.33 ± 7.78, P < 0.05) and the percentage of the small LDL subfraction (1.09 ± 1.12 vs. 3.07 ± 3.09, P < 0.05). Conclusions: Treatment with 1200 mg/day XZK for 8 weeks significantly decreased the atherogenic small LDL subfraction and reduced oxidative stress and inflammatory markers, in addition to affecting the lipid profile, suggesting multiple beneficial effects in coronary artery disease. Keywords: XueZhiKang, Hyperlipidemia, Low-density lipoprotein cholesterol subfraction, Oxidized LDL, Interleukin-6 |
| format |
article |
| author |
Rui-Xia Xu Yan Zhang Yuan-Lin Guo Chun-Yan Ma Yu-Hong Yao Sha Li Xiao-Lin Li Ping Qing Ying Gao Na-Qiong Wu Cheng-Gang Zhu Geng Liu Qian Dong Jing Sun Jian-Jun Li |
| author_facet |
Rui-Xia Xu Yan Zhang Yuan-Lin Guo Chun-Yan Ma Yu-Hong Yao Sha Li Xiao-Lin Li Ping Qing Ying Gao Na-Qiong Wu Cheng-Gang Zhu Geng Liu Qian Dong Jing Sun Jian-Jun Li |
| author_sort |
Rui-Xia Xu |
| title |
Novel findings in relation to multiple anti-atherosclerotic effects of XueZhiKang in humans |
| title_short |
Novel findings in relation to multiple anti-atherosclerotic effects of XueZhiKang in humans |
| title_full |
Novel findings in relation to multiple anti-atherosclerotic effects of XueZhiKang in humans |
| title_fullStr |
Novel findings in relation to multiple anti-atherosclerotic effects of XueZhiKang in humans |
| title_full_unstemmed |
Novel findings in relation to multiple anti-atherosclerotic effects of XueZhiKang in humans |
| title_sort |
novel findings in relation to multiple anti-atherosclerotic effects of xuezhikang in humans |
| publisher |
KeAi Communications Co., Ltd. |
| publishDate |
2018 |
| url |
https://doaj.org/article/4208be07430f456da1559d68db4ce26a |
| work_keys_str_mv |
AT ruixiaxu novelfindingsinrelationtomultipleantiatheroscleroticeffectsofxuezhikanginhumans AT yanzhang novelfindingsinrelationtomultipleantiatheroscleroticeffectsofxuezhikanginhumans AT yuanlinguo novelfindingsinrelationtomultipleantiatheroscleroticeffectsofxuezhikanginhumans AT chunyanma novelfindingsinrelationtomultipleantiatheroscleroticeffectsofxuezhikanginhumans AT yuhongyao novelfindingsinrelationtomultipleantiatheroscleroticeffectsofxuezhikanginhumans AT shali novelfindingsinrelationtomultipleantiatheroscleroticeffectsofxuezhikanginhumans AT xiaolinli novelfindingsinrelationtomultipleantiatheroscleroticeffectsofxuezhikanginhumans AT pingqing novelfindingsinrelationtomultipleantiatheroscleroticeffectsofxuezhikanginhumans AT yinggao novelfindingsinrelationtomultipleantiatheroscleroticeffectsofxuezhikanginhumans AT naqiongwu novelfindingsinrelationtomultipleantiatheroscleroticeffectsofxuezhikanginhumans AT chenggangzhu novelfindingsinrelationtomultipleantiatheroscleroticeffectsofxuezhikanginhumans AT gengliu novelfindingsinrelationtomultipleantiatheroscleroticeffectsofxuezhikanginhumans AT qiandong novelfindingsinrelationtomultipleantiatheroscleroticeffectsofxuezhikanginhumans AT jingsun novelfindingsinrelationtomultipleantiatheroscleroticeffectsofxuezhikanginhumans AT jianjunli novelfindingsinrelationtomultipleantiatheroscleroticeffectsofxuezhikanginhumans |
| _version_ |
1718393205218607104 |